TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipelineTar ...
Interim results of the ongoing phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors
Thierra Guillaudeux, PhD, Chief Scientific Officer, Kineta Inc American Association of Cancer Research Annual Meeting | April 8, 2024
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts No dose limiting toxicities observed at any dose level Cleared ...
VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid Leukemia
Thierry Guillaudeux; Shaarwari Sridhar; Emily Frazier; Yulia Ovechkina; Shawn Iadonato AACR Journal: Blood Cancer Discovery | March 4, 2024
Kineta Announces Restructuring and Exploration of Strategic Alternatives
SEATTLE, Feb. 29, 2024 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
SEATTLE, Feb. 22, 2024 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...
Kineta to Present at Upcoming Investor Conferences
SEATTLE, Feb. 14, 2024 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
SEATTLE, Feb. 07, 2024 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
SEATTLE, Jan. 04, 2024 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...
A highly potent anti-VISTA antibody KVA12123 – a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
Shawn Iadonato, Yulia Ovechkina, Kurt Lustig, Jessica Cross, Nathan Eyde, Emily Frazier, Neda Kabi, Chen Katz, Remington Lance, David Peckham, Shaarwari Sridhar, Carla Talbaux, Isabelle Tihista, Mei X ...